Blog
RSS FeedPosted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 01 Oct 2018
Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation
1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 14 Jun 2018
Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany
13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...
Posted by Michael Wonder on 11 Jun 2018
Rheumatoid arthritis: few indications of the benefits of certain biologics over others
6 June 2018 - Still no long-term studies and little direct comparisons of biologics/first-time also first-line therapy examined. ...
Posted by Michael Wonder on 01 Mar 2018
Dupilumab in atopic dermatitis: indication of added benefit in adults
1 March 2018 - Significant benefits in terms of symptoms and especially in quality of life/dossier provides meaningful data. ...
Posted by Michael Wonder on 18 Jan 2018
Early benefit assessments: the 220th dossier evaluation completed at the turn of the year
18 January 2018 - Oncology remains by far the most common indication. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
Posted by Michael Wonder on 03 Jul 2017
IQWiG finds no additional benefit for tenofovir alafenamide fumarate in chronic hepatitis B
3 July 2017 - The anti-viral medicine tenofovir alafenamide fumarate has been used in various combinations since 2015 in HIV ...
Posted by Michael Wonder on 01 Jun 2017
Secukinumab and ixekizumab in psoriasis: significant additional benefit for certain patients
1 June 2017 - The manufacturer of secukinumab has applied for a new benefit assessment as new scientific evidence emerges. ...
Posted by Michael Wonder on 16 May 2017
Pembrolizumab in non-small-cell lung cancer: a hint of considerable added benefit
15 May 2017 - Patients in the relevant subpopulation of the analysed study survived longer. ...
Posted by Michael Wonder on 13 Apr 2017
Clinuvel reaches agreement on German Scenesse pricing through AMNOG Arbitration Board
12 April 2017 - Clinuvel today announced that it had reached agreement with the German National Association of Statutory Health ...
Posted by Michael Wonder on 29 Mar 2017
German Federal Joint Committee (G-BA) confirms additional benefit of anti-cancer agent Kisplyx (lenvatinib mesylate) in treatment of advanced renal cell carcinoma
28 March 2017 - Eisai announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house ...
Posted by Michael Wonder on 01 Mar 2017
Palbociclib in advanced breast cancer: disadvantages in certain patients
1 March 2017 - More frequent severe side effects in first-line therapy after menopause/missing data for other patients. ...